Introduction
============

Cancer is the main disease that endangers human life worldwide. The incidence of cancer remains grim that 1.7 million new cancer cases and 0.6 million cancer deaths are projected to occur in USA in 2017.[@b1-ott-11-4913] Since cancer often leads to poor survival and a marked decline in quality of life, effective and safe therapies for prolonging cancer survival are urgently needed.

Beta-blockers have been considered as a safe cardiovascular treatment for decades.[@b2-ott-11-4913] At present, the beta-adrenergic receptor downstream signaling pathway is certified as an important regulator of progression and metastasis of some important tumors,[@b3-ott-11-4913] making beta-blockers a new alternative for cancer adjuvant chemotherapy.[@b4-ott-11-4913] So far, a growing number of studies have supported the use of beta-blockers in prolonging survival of cancer patients,[@b8-ott-11-4913]--[@b30-ott-11-4913] but several studies have put forward controversial conclusions.[@b31-ott-11-4913]--[@b43-ott-11-4913]

The purpose of this study was to use meta-analysis to quantitatively and comprehensively summarize the evidence for the relationship between beta-blocker exposure and survival outcomes of various cancers.

Materials and methods
=====================

Search strategy
---------------

Under the guidance of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA), we conducted this meta-analysis. To identify the studies of interest, we systematically searched PubMed (Supplementary material online file), Embase, Cochrane Library, and Web of Science for research reports published up to September 1, 2017. Search terms included: {Adrenergic beta-Antagonist(s), beta-blocker(s), atenolol, bisoprolol, carvedilol, metoprolol, propranolol, sotalol, timolol, arotinolol, betaxolol, bevan-tolol, carteolol or celiprolol} combined with {cancer(s), carcinoma(s), malignancy(ies), neoplasm(s) or tumour(s)} and {prognosis, survival or mortality}. We scanned the titles and abstracts of the studies identified in the initial search, excluding those apparently unrelated. The full text of the remaining articles was read to determine the studies that can be included. In addition, we have further studied the reference lists of articles for additional studies.

Inclusion and exclusion criteria
--------------------------------

Our inclusion criteria were: 1) case--control or cohort studies or randomized controlled trials (RCTs); 2) patients with cancer; 3) reported at least 20 patients; 4) evaluated the therapeutic value of beta-blockers in cancer prognosis; 5) compared beta-blocker users with non-users in patients; 6) reported survival outcomes like overall survival (OS), all-cause mortality, cancer-specific survival (CSS), disease-free survival (DFS), progression-free survival (PFS), and recurrence-free survival (RFS); 7) reported HR with 95% CI for survival of comparison between exposure group and control group or HR could be obtained from other sufficient information.

Articles were excluded from the analyses for any of the following reasons: 1) reviews, commentaries, experimental laboratory articles, animal studies, or letters; 2) repeated publications; 3) impossible to calculate HR with 95% CI for survival from the paper.

Data extraction
---------------

The following information was extracted from each study: 1) publication data: first author's name, publication year, and geographical location of the study; 2) study design; 3) number and characteristics of participants; 4) types of beta-blockers used; 5) HR estimates with their 95% CIs and control for multiple factors by matching or adjustments. If the HR and 95% CI could not be obtained directly, they were estimated from Kaplan--Meier curves.[@b5-ott-11-4913]

Quality assessment
------------------

Quality of the included studies was assessed using the Newcastle--Ottawa Quality Assessment Scale (NOS). Studies of medium quality scored 6--7 points. This assessment was completed by two investigators (ZN and XQ) independently, and any disagreements were solved by a revaluation of the original article with a third author (XH).

Statistical analysis
--------------------

For the meta-analysis, we calculated pooled HRs with 95% CI for all the studies. We used the Cochran's *Q*-test to examine whether the results of the studies were homogeneous. The *P*-value \<0.10 for *Q*-test indicated heterogeneity. Quantity of *I*^2^ was also calculated to describe the percentage variation across studies due to heterogeneity. We regarded an *I*^2^ value \>50% as indicative of significant heterogeneity. A fixed-effects model (inverse variance method) was used to calculate pooled results when no heterogeneity existed among the included studies; otherwise, a random-effects model (DerSimonian and Laird method) was used with the weights inversely proportional to the variance of hazard ratio of each trial.[@b6-ott-11-4913],[@b7-ott-11-4913] To identify potential sources of between-study heterogeneity, subgroup analyses were conducted by stratifying ethnicity, duration of drug use, cancer stage, sample size, beta-blocker type, chronological order of drug use, and different types of cancers. We conducted sensitivity analysis to determine the relative effect of a particular study on the meta-analysis model. To assess the influence of potential causes, meta-regression models were fitted separately for each cause except for beta-blocker therapy. The Begg's adjusted rank correlation test and the Egger's regression asymmetry tests were used to evaluate the effects of publication bias. All analyses were conducted using Stata 12.0 software (Markummitchell, Torrance, CA, USA), and we read Kaplan--Meier curves with Engauge Digitizer version 9.8.

Results
=======

Study search and characteristics
--------------------------------

The flow of literature selection applying the systematic search and selection strategies to identify qualified reports is shown in [Figure 1](#f1-ott-11-4913){ref-type="fig"}. Six hundred and thirty studies were initially identified by the search. Of these, we retrieved 49 potential studies by filtering the titles and abstracts. Due to insufficient information (12 studies) or including the same patients (one study), 13 studies were excluded after further comprehensive review. Two studies were conducted in the same institute, but as the sample patients were at different stages and were treated differently, we considered them to be different cohorts.[@b8-ott-11-4913],[@b9-ott-11-4913] Finally, a total of 36 studies were included in the pooled analyses.

[Table 1](#t1-ott-11-4913){ref-type="table"} showed the characteristics of the 36 studies. The articles were published from 2011 to 2017, which included 319,006 patients. Of them, 35 studies utilized cohort design[@b8-ott-11-4913]--[@b10-ott-11-4913],[@b12-ott-11-4913]--[@b43-ott-11-4913] and one study used case--control design.[@b11-ott-11-4913] Besides, there were 22 hospital-based studies[@b9-ott-11-4913]--[@b11-ott-11-4913],[@b14-ott-11-4913]--[@b16-ott-11-4913],[@b18-ott-11-4913],[@b19-ott-11-4913],[@b21-ott-11-4913],[@b23-ott-11-4913],[@b24-ott-11-4913],[@b26-ott-11-4913]--[@b31-ott-11-4913],[@b33-ott-11-4913]--[@b35-ott-11-4913],[@b40-ott-11-4913],[@b41-ott-11-4913] and 14 population-based studies.[@b8-ott-11-4913],[@b12-ott-11-4913],[@b13-ott-11-4913],[@b17-ott-11-4913],[@b20-ott-11-4913],[@b22-ott-11-4913],[@b25-ott-11-4913],[@b32-ott-11-4913],[@b36-ott-11-4913]--[@b39-ott-11-4913],[@b42-ott-11-4913],[@b43-ott-11-4913] Overall, all the 36 studies reported the prognostic value of beta-blockers in the survival of cancer patients.

Quality assessment
------------------

While there was small variation in the methodological quality of the included studies, all 36 included studies were judged as moderate to relative high quality according to the NOS assessment tool, with scores of 6 (11 studies), 7 (20 studies), and 8 (five studies, [Table S1](#SD4-ott-11-4913){ref-type="supplementary-material"}).

Beta-blockers and survival of cancer
------------------------------------

### Meta-analysis of overall survival

As displayed in [Figure 2A](#f2-ott-11-4913){ref-type="fig"}, the forest plot showed that beta-blocker use was not associated with OS. The pooled HR was 0.94 (95% CI: 0.87--1.03, *P*=0.172) from 22 observational studies. Considering the high heterogeneity (*I*^2^=83.3%, *P*\<0.001), we used random-effects model to pool the studies.

### Meta-analysis of all-cause mortality

Twelve studies focused on beta-blocker use and all-cause mortality. A random-effects model was used and the combined HR of 0.99 (95% CI: 0.94--1.05, *P*=0.807, [Figure 2B](#f2-ott-11-4913){ref-type="fig"}) showed that beta-blocker use was also not correlated with all-cause mortality.

### Meta-analysis of cancer-specific survival

Thirteen studies presented the data concerning the association between beta-blocker use and CSS ([Figure 2C](#f2-ott-11-4913){ref-type="fig"}). We calculated that beta-blocker use was significantly correlated with long CSS, with a pooled HR of 0.78 (95% CI: 0.65--0.95, *P*=0.012) by using a random-effects model.

### Meta-analysis of disease-free survival

Four studies reported the data on beta-blocker use and DFS outcome. The pooled HR was 0.59 (95% CI: 0.30--1.17, *P*=0.134, [Figure 2D](#f2-ott-11-4913){ref-type="fig"}) with significant heterogeneity between studies (*I*^2^=89.5%, *P*\<0.001), which demonstrated that beta-blocker use was also prominently not related to DFS.

### Meta-analysis of progression-free survival

The data on beta-blocker use and PFS outcome was presented in six studies. Meta-analysis adopting the fixed-effects model revealed that beta-blocker use was not associated with PFS (HR=0.90, 95% CI: 0.79--1.02, *P*=0.087, [Figure 2E](#f2-ott-11-4913){ref-type="fig"}) and exhibited no heterogeneity (*I*^2^=0.00%, *P*=0.603).

### Meta-analysis of recurrence-free survival

Four studies provided sufficient data on beta-blocker use and RFS outcome. The pooled HR was 0.99 (95% CI: 0.76--1.28, *P*=0.944, [Figure 2F](#f2-ott-11-4913){ref-type="fig"}) by a random-effects model. Beta-blocker use was also significantly not related to RFS.

Subgroup analysis
-----------------

To deeply explore the relationship between beta-blocker use and OS, we performed subgroup analysis based on ethnicity, duration of drug use, cancer stage, sample size, beta-blocker type, chronological order of drug use, and different types of cancers. The median values of original data from included studies in "duration of drug use" and "sample size" were chosen as cut-off values to divide our subgroups. The results are summarized in [Table 2](#t2-ott-11-4913){ref-type="table"}, with the corresponding forest plots presented in [Figure S1](#SD1-ott-11-4913){ref-type="supplementary-material"}.

The subgroups of sample size and ethnicity demonstrated no significant effect of beta-blocker use on OS. Similarly, beta-blocker showed no obvious impact on OS for patients with duration of drug use more than 2 years (HR=1.03, 95% CI: 0.93--1.14, *P*=0.617) or patients with duration of drug use less than 2 years (HR=1.01, 95% CI: 0.91--1.11, *P*=0.897). Additionally, the subgroup analysis indicated that the administration of beta-blockers had no relationship with longer OS when the meta-analysis was restricted to patients with cancer in I/II stage (HR=0.97, 95% CI: 0.89--1.06, *P*=0.507) or cancer in III/IV stage (HR=1.04, 95% CI: 0.94--1.14, *P*=0.468). In addition, the studies using selective beta-blocker (HR=0.93, 95% CI: 0.83--1.05, *P*=0.243) and non-selective beta-blocker (HR=1.04, 95% CI: 0.89--1.22, *P*=0.596) were found to have no effect on OS. However, beta-blocker showed a more positive effect on OS for patients with time-fixed post-diagnostic beta-blocker use (HR=0.65, 95% CI: 0.43--0.99, *P*=0.046) than pre-diagnostic beta-blocker use (HR=1.03, 95% CI: 0.95--1.11, *P*=0.493) and time-dependent post-diagnostic beta-blocker use (HR=0.87, 95% CI: 0.59--1.30, *P*=0.508).

Analysis according to cancer type showed predominantly longer OS in ovarian cancer (HR=0.59, 95% CI: 0.36--0.96, *P*=0.034), pancreatic cancer (HR=0.85, 95% CI: 0.75--0.97, *P*=0.014), and melanoma (HR=0.81, 95% CI: 0.67--0.97, *P*=0.026), but no effects on lung cancer (HR=1, 95% CI: 0.96--1.05, *P*=0.818), breast cancer (HR=0.97, 95% CI: 0.78--1.21, *P*=0.783), colorectal cancer (HR=1.16; 95% CI: 0.84--1.61, *P*=0.353), and mixed cancer (HR=1.00; 95% CI: 0.83--1.21, *P*=0.974). Owing to the small numbers of studies and lack of information, subgroup analyses were not performed on other survival outcomes.

Sensitivity analysis
--------------------

Sensitivity analysis was conducted on different survival outcomes. The meta-analyses of beta-blockers and survival were performed by removing a single study in turn. After removing the study results, the comprehensive estimation direction and amplitude of OS, all-cause mortality, CSS, DFS, PFS, and RFS were not significantly changed, indicating that the reliability of the meta-analysis was good and the results were not affected by any research ([Figure 3](#f3-ott-11-4913){ref-type="fig"}). In addition, sensitivity analyses were also conducted in those studies whose HR and 95% CI values were presented in original articles (not calculated from the Kaplan--Meier plots) ([Figure S2](#SD2-ott-11-4913){ref-type="supplementary-material"}) and whose NOS score was ≥7 ([Figure S3](#SD3-ott-11-4913){ref-type="supplementary-material"}). These factors did not affect the main results.

Publication bias
----------------

The funnel plot revealed no evidence of publication bias in the meta-analysis of beta-blocker use and OS ([Figure 4A](#f4-ott-11-4913){ref-type="fig"}, Egger's test: *P*-value =0.358; Begg's test: *P*-value =0.115). There was no potential publication bias on beta-blocker use and all-cause mortality as well ([Figure 4B](#f4-ott-11-4913){ref-type="fig"}, Egger's test: *P*-value =0.261; Begg's test: *P*-value =0.260). Besides, there was also no potential publication bias on beta-blocker use, CSS, DFS, PFS, and RFS of cancer patients ([Figure 4C--F](#f4-ott-11-4913){ref-type="fig"}).

Meta-regression
---------------

The meta-regression analysis was performed to investigate the effects of various cohort study characteristics on the study estimates of the HRs. We grouped the studies according to specific characteristics, the size of sample, the sex of patients, the cancer sites, study duration, and study quality. There was no inverse association between sample size (*P*=0.892), sex of the patients (*P*=0.135), cancer sites (*P*=0.364), study duration (*P*=0.076), and study quality (*P*=0.571). Because of the lack of information, meta-regression was not performed on other survival outcomes.

Discussion
==========

This meta-analysis summarizes 36 currently published studies examining the association between beta-blocker use and prognosis of cancer across a wide range of geographic regions and cancer types. Overall, the administration of beta-blocker was not associated with OS, all-cause mortality, DFS, PFS and RFS of cancer patients. However, beta-blocker use was significantly correlated with long CSS (HR=0.78, 95% CI: 0.65--0.95). Since the patients included in the clinical trials differed in stages, therapies, and so on, the heterogeneity was inescapable. Then we conducted subgroup analysis. Among the cancer types, positive associations between beta-blocker use and cancer prognosis were observed in breast cancer, pancreatic cancer, and melanoma, but could not be detected in lung cancer, ovarian cancer, colorectal cancer, and mixed cancer. Interestingly, beta-blocker use is associated with improved survival only among patients with ovarian cancer, pancreatic cancer, and melanoma. However, the results should be interpreted carefully because the number of studies on these three cancers was small. In addition, the results showed that beta-blockers prolonged OS for patients with time-fixed post-diagnostic beta-blocker use. Generally, the subgroups of cancer stage, beta-blocker type, cumulative beta-blocker use, sample size, and ethnicity demonstrated no significant effect of beta-blocker on longer OS. Hence, we did not find a beneficial effect of beta-blocker use on cancer survival.

To our knowledge, this meta-analysis is the fourth one to be conducted on beta-blocker use and prognosis in various cancers. Indeed, this analysis objectively confirmed the latest development in this topic. All the previous three articles drew a conclusion that beta-blocker use could prolong the survival of cancer patients,[@b44-ott-11-4913]--[@b46-ott-11-4913] but our current analysis showed an opposite conclusion that there is generally no relationship between beta-blocker use and cancer prognosis.

We then hypothesize some possible reasons for this conclusion. Preclinical studies have suggested that β-blockers play an anti-cancer role in multiple kinds of cancers by targeting at β-adrenergic signaling pathway.[@b47-ott-11-4913],[@b48-ott-11-4913] β-blockers can inhibit multiple processes of tumor progression and metastasis, including the inhibition of tumor cell proliferation, migration, invasion, as well as resistance to tumor angiogenesis and metastasis.[@b3-ott-11-4913] Although the basic research may be effective, it is not recommended for speculating on the clinical survival of cancer patients due to the current evidence of evidence-based medicine. Beta-blocker is not a necessary medication for general adjuvant chemotherapy in cancer patients.[@b49-ott-11-4913]

Since cardiovascular diseases are common in the population, cancer patients frequently receive cardiovascular medications, including beta-blockers,[@b2-ott-11-4913] but beta-blockers might not be recommended for chemotherapy in the absence of other indications. Further studies should be done to investigate the relationship between cancer survival and beta-blocker use in cancer patients without cardiovascular disease. Additionally, different effects in different cancers might have contributed to the lack of a discernible relationship between beta-blockers and OS of various cancers in the current studies. To find out the actual concrete relationship between the two, further analysis can be confined to beta-blocker use and one specific cancer based on a large enough population. Besides, beta-blockers themselves might have some undefined side effects on other organ systems, which might lead to cancer progression.[@b50-ott-11-4913]

However, there are still several limitations in this study. First, the studies included in this analysis were all cohort studies or case--control studies, as there were no RCTs yet investigating this topic. Second, while sensitivity analysis supported the stability of our results and a relatively large number of studies were included, we should still carefully interpret the results. The heterogeneity found in the study may be attributed to the multivariable influence factors in some studies. Third, the power of Begg's and Egger's tests to detect bias will be low with small number of studies, and when the between-study heterogeneity is large, none of the bias detection tests work well. Fourth, the dose--response analyses were not carried out due to a limited amount of literature.

Despite the limitations, there are several strengths in our study compared with previous meta-analyses. First, our current analysis showed a completely different main conclusion from the previous meta-analyses that there was no relationship between beta-blocker use and cancer prognosis. Second, we separated all-cause mortality from OS to make the analysis more precise. Third, we included 36 studies involving 319,006 patients, which was a larger number of patients than previous meta-analyses. Fourth, we discussed almost all variables that could describe the outcome of survival, including OS, all-cause mortality, CSS, DFS, PFS, and RFS.

Conclusion
==========

The beta-blocker administration is not associated with cancer prognosis except for the positive effect on long CSS. Moreover, there are apparent protective effects of beta-blocker use in ovarian cancer, pancreatic cancer, and melanoma. We need more high-quality studies, such as RCTs, to confirm this conclusion in the future.

Supplementary materials
=======================

###### 

Subgroup analysis on beta-blocker use and OS in patients with non-Europeans (**A**), Europeans (**B**); duration of drug use \>2 years (**C**), duration of drug use \<2 years (**D**); Stage I/II (**E**), Stage III/IV (**F**); sample size \>80 (**G**), sample size \<80 (**H**); non-selective beta-blocker (**I**), selective blocker-type (**J**); pre-diagnostic beta-blocker use (**K**), post-diagnostic beta-blocker use (time-fixed) (**L**), post-diagnostic beta-blocker use (time-dependent) (**M**); lung cancer (**N**), melanoma (**O**), mixed cancer (**P**), colorectal cancer (**Q**), ovarian cancer (**R**), breast cancer (**S**), and pancreatic cancer (**T**).

**Note:** Weights are from random-effects analysis. The numbers in parentheses indicate the different included studies in the same year.

###### 

Sensitivity analysis of beta-blocker use on OS (**A**), all-cause mortality (**B**), CSS (**C**), DFS (**D**), PFS (**E**), and RFS (**F**) in studies except the studies obtaining estimates from KM plots.

**Abbreviations:** OS, overall survival; CSS, cancer-specific survival; DFS, disease-free survival; PFS, progression-free survival; RFS, recurrence-free survival; KM, kaplanmeier.

###### 

Sensitivity analysis of beta-blocker use on OS (**A**), all-cause mortality (**B**), CSS (**C**), PFS (**D**), and RFS (**E**) in high-quality studies (NOS score ≥7).

**Abbreviations:** OS, overall survival; CSS, cancer-specific survival; PFS, progression-free survival; RFS, recurrence-free survival; NOS, Newcastle--Ottawa Quality Assessment Scale.

###### 

Quality assessment of the included studies

  Subjects                                                                                                                                                                                Items                                                                                                     Standards                                                                                      Reference no.                                                                                                                                           
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------- --------------- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
  Selection                                                                                                                                                                               1\. Is the case definition adequate?                                                                      1\. Yes, with independent validation[\*](#tfn3-ott-11-4913){ref-type="table-fn"}               1               1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1
  2\. Yes, eg, record linkage or based on self-reports                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  3\. No description                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  2\. Representativeness of the cases                                                                                                                                                     1\. Consecutive or obviously representative series of cases[\*](#tfn3-ott-11-4913){ref-type="table-fn"}   1                                                                                              1               1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   
  2\. Potential for selection biases or not stated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  3\. Selection of controls                                                                                                                                                               1\. Community controls[\*](#tfn3-ott-11-4913){ref-type="table-fn"}                                        1                                                                                                                      1   1       1       1           1       1       1   1                           1               1   1   1   1           1   1   
  2\. Hospital controls                                                                                                                                                                                                                                                                             0                                                                                              0               0           0       0       0   0       0       0   0       0   0   0   0   0   0       0   0   0                   0   0               
  3\. No description                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  4\. Definition of controls                                                                                                                                                              1\. No history of disease (end point)[\*](#tfn3-ott-11-4913){ref-type="table-fn"}                                                                                                                                                                                                                                                                                
  2\. No description of source                                                                                                                                                            0                                                                                                         0                                                                                              0               0   0   0   0   0   0   0   0   0   0   0   0   0   0   0   0   0   0   0   0   0   0   0   0   0   0   0   0   0   0   0   0   0       
  Comparability                                                                                                                                                                           Comparability ofcases and controls on the basis of the design or analysis                                 1\. Study controls for the most important factor[\*](#tfn3-ott-11-4913){ref-type="table-fn"}   1               1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1
  2\. Study controls for any additional factor (this criteria could be modified to indicate specific control for a second important factor[\*](#tfn3-ott-11-4913){ref-type="table-fn"})   1                                                                                                         1                                                                                              1               1   1   1   1   0   1   1   1   1   1   1   1   1   0   1   1   0   1   1   1   1   0   1   1   1   0   1   0   0   1   0   0   1       
  Exposure                                                                                                                                                                                1\. Ascertainment of exposure                                                                             1\. Secure record (eg, surgical records)[\*](#tfn3-ott-11-4913){ref-type="table-fn"}           1               1   1   1   1   1                                                   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1       1
  2\. Structured interview where blind to case/control status[\*](#tfn3-ott-11-4913){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  3\. Interview not blinded to case/control status                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  4\. Written self-report or medical record only                                                                                                                                                                                                                                                                                                                                                                               1   1   1   1   1   1   1   1   1   1   1   1                                                                               
  5\. No description                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           0           
  2\. Same method of ascertainment for cases and controls                                                                                                                                 1\. Yes[\*](#tfn3-ott-11-4913){ref-type="table-fn"}                                                       1                                                                                              1               1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   1   
  2\. No                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  3\. Nonresponse rate                                                                                                                                                                    1\. Same rate for both groups[\*](#tfn3-ott-11-4913){ref-type="table-fn"}                                 1                                                                                              1               1   1   1   1   1   1           1   1   1           1   1   1   1   1       1   1       1   1   1   1                   1   1   1       
  2\. Nonrespondents described                                                                                                                                                                                                                                                                                                                                                                                                         0   0               0   0                       0           0                   0   0   0   0               0       
  3\. Rate different and no designation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                          8                                                                                                         7                                                                                              7               7   8   8   7   7   6   7   7   7   8   6   7   7   7   8   7   6   6   7   7   6   7   7   7   7   6   7   6   6   7   6   6   7       

**Note:**

Indicates 1 score.
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![PRISMA flowchart of article selection for this meta-analysis.\
**Abbreviation:** PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.](ott-11-4913Fig1){#f1-ott-11-4913}

![Forest plots showing the effects of beta-blocker use on OS (**A**), all-cause mortality (**B**), CSS (**C**), DFS (**D**), PFS (**E**), and RFS (**F**).\
**Notes:** Weights are from random-effects analysis. The numbers in parentheses indicate the different included studies in the same year.\
**Abbreviations:** OS, overall survival; CSS, cancer-specific survival; DFS, disease-free survival; PFS, progression-free survival; RFS, recurrence-free survival.](ott-11-4913Fig2){#f2-ott-11-4913}

![Sensitivity analysis of beta-blocker use on OS (**A**), all-cause mortality (**B**), CSS (**C**), DFS (**D**), PFS (**E**), and RFS (**F**).\
**Abbreviations:** OS, overall survival; CSS, cancer-specific survival; DFS, disease-free survival; PFS, progression-free survival; RFS, recurrence-free survival.](ott-11-4913Fig3){#f3-ott-11-4913}

![Funnel plot of Begg's test of beta blocker use on OS (**A**), all-cause mortality (**B**), CSS (**C**), DFS (**D**), PFS (**E**), and RFS (**F**).\
**Abbreviations:** OS, overall survival; CSS, cancer-specific survival; DFS, disease-free survival; PFS, progression-free survival; RFS, recurrence-free survival; SE, standard error.](ott-11-4913Fig4){#f4-ott-11-4913}

###### 

Characteristics of studies included for meta-analysis

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference   Study                           Country                   Duration     Sample size   Median age (years)   Study design       Cancer type                                     Stage                                    Surgery                                              Beta-blocker type                                                                                      No. of patients   Exposure category   Follow-up time (months)                                 Treatment                                   HR                                                                                           95% CI   Survival outcome   Multivariable analysis   Adjusted for   Study quality (NOS score)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  ----------- ------------------------------- ------------------------- ------------ ------------- -------------------- ------------------ ----------------------------------------------- ---------------------------------------- ---------------------------------------------------- ------------------------------------------------------------------------------------------------------ ----------------- ------------------- ------------------------------------------------------- ------------------------------------------- -------------------------------------------------------------------------------------------- -------- ------------------ ------------------------ -------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---
  8           Grytli et al (2013)             Norway                    2004--2009   655           72                   PB cohort          Prostate cancer                                 I/II 60.1%, III/IV 39.9%                 NR                                                   Mixed: beta selective (80.2%); non-selective (19.8%)                                                   80                575                 Pre-diagnostic beta-blocker use                         122                                         ADT or not                                                                                   0.88     0.56--1.38         OS                       Yes            Age at diagnosis, metastasis at diagnosis, and level of education                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        8

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       0.79     0.68--0.91         CSS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  9           Grytli et al (2014)             Norway                    2000--2011   3,561         76.3                 HB cohort          Prostate cancer                                 ≤T2A 14.9%; T2b--T2c 18.5%; ≥T3a 66.6%   NR                                                   Mixed: beta 1 selective (77.9%); non-selective (3.0%); alpha and beta mixed (4.5%)                     1,115             2,446               Pre-diagnostic beta-blocker use                         39                                          RT or radical prostatectomy                                                                  0.96     0.87--1.05         OS                       Yes            Age, prostate-specific antigen level, Gleason score, clinical T stage, presence and type of metastases, performance status, and androgen deprivation, therapy initiated within 6 months after diagnosis                                                                                                                                                                                                                                                                                                                                                                                                                                  7

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       0.97     0.72--1.31         CSS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  10          Al-Niaimi et al (2016)          USA                       2000--2010   185           66.2 63.8            HB cohort          Ovarian cancer                                  I/II 26%, III/IV 74%                     Yes                                                  NR                                                                                                     70                115                 Post-diagnostic beta-blocker use (time-dependent)       91                                          CT                                                                                           0.68     0.46--0.99         OS                       Yes            Age, stage, grade, cytoreduction status, BMI, and presence or absence of diabetes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        7

  11          Aydiner et al (2013)            Turkey                    2003--2011   107           61 (42--81)          HB case--control   Non-small-cell lung cancer                      NR                                       Mixed                                                Mixed                                                                                                  35                72                  Post-diagnostic beta-blocker use (time-fixed)           17.8 (1--102)                               CT                                                                                           0.69     0.36--1.34         OS                       Yes            Age, sex, performance status, histologic subtype, smoking status, presence of comorbidities (COPD, IHD, HT, and DM)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      7

  12          Barron et al (2011)             Ireland/USA               2001--2006   4,808         69.1 71              PB cohort          Breast cancer                                   I/II 75.6%, III/IV 24.4%                 NR                                                   Beta non-selective                                                                                     70                4,738               Pre-diagnostic beta-blocker use                         42 43.2\                                    CT or not                                                                                    0.19     0.06--0.60         OS                       Yes            Age, stage, grade, and comorbidity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       7
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              32.4 36                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  12          Barron et al (2011)             Ireland/USA               2001--2006   5,263         69.1 71              PB cohort          Breast cancer                                   I/II 75.6%, III/IV 24.4%                 NR                                                   Beta selective                                                                                         525               4,738               Pre-diagnostic beta-blocker use                         42 43.2\                                    CT or not                                                                                    1.08     0.84--1.40         OS                       Yes            Age, stage, grade, and comorbidity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       7
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              32.4 36                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  12          Barron et al (2011)             Ireland/USA               2001--2006   5,801         69.1 71              PB cohort          Breast cancer                                   I/II 75.6%, III/IV 24.4%                 NR                                                   Mixed: beta selective (88%); non-selective (12%)                                                       595               4,738               Pre-diagnostic beta-blocker use                         42 43.2\                                    CT or not                                                                                    1.08     0.84--1.39         CSS                      Yes            Age, stage, grade, and comorbidity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       7
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              32.4 36                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  13          Beg et al (2017)                USA                       2006--2009   13,702        76                   PB cohort          Pancreatic adenocarcinoma                       I/II 38.1%, III/IV 61.9%                 Mixed 69.3%                                          NR                                                                                                     5,209             8,493               NR                                                      NR                                          NR                                                                                           0.9      0.85--0.95         OS                       Yes            Age, sex, race, stage at diagnosis, site of cancer, and Charlson comorbidity index                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       8

  14          Bir et al (2015)                USA                       2001--2013   225           57.34± 10.98         HB cohort          Metastatic brain tumors                         NR                                       Yes                                                  Beta 1 selective                                                                                       40                185                 NR                                                      10.57                                       GKRS                                                                                         1.08     0.65--1.79         OS                       Yes            MBT kind, metastasis, tumor recurrence, tumor response, GKRS, prognostic factor                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          7

  15          De Giorgi et al (2013)          Italy                     1993--2009   741           64 53                HB cohort          Thick melanoma                                  NR                                       Mixed                                                Mixed: beta 1 selective (73%); non-selective (27%)                                                     79                662                 Post-diagnostic beta-blocker use (time-dependent)       50.4                                        NR                                                                                           0.03     0.01--0.17         DFS                      Yes            Age, Breslow thickness, and ulceration                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   7

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       0.04     0.00--0.38         OS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  16          Diaz et al (2012)               USA                       1996--2006   248           67                   HB cohort          Ovarian cancer                                  III/IV 100%                              Yes                                                  Mixed: beta 1 selective (75%); non-selective (13%); mixed alpha and beta adrenergic antagonist (13%)   23                225                 NR                                                      NR                                          CT                                                                                           0.56     0.43--1.26         OS                       Yes            Age, stage, grade, and cytoreduction status                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              6

  17          Ganz et al (2011)               USA                       1997--2002   1,779         NR                   PB cohort          Breast cancer                                   I/II 96.9%, III/IV 3.1%                  NR                                                   Mixed: beta selective (86%); non-selective (14%)                                                       204               1,372               NR                                                      98.4                                        CT, RT, both or none                                                                         1.04     0.72--1.51         OS                       Yes            Age at diagnosis, race, stage of disease, pre-diagnosis BMI, adjuvant treatment, hormone receptor status, tamoxifen use, and self-reported hypertension and diabetes                                                                                                                                                                                                                                                                                                                                                                                                                                                                     8

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       0.86     0.57--1.32         RFS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       0.76     0.44--1.33         CSS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  18          Giampieri et al (2015)          Italy                     2010--2013   235           NR                   HB cohort          Colorectal cancer                               NR                                       NR                                                   NR                                                                                                     29                206                 Pre-diagnostic beta-blocker use                         NR                                          CT or with bevacizumab                                                                       1.51     0.88--2.31         OS                       Yes            Age, sex, and site of metastases, previous adjuvant chemotherapy, and ECOG performance status                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            7

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       1.19     0.81--1.72         PFS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  19          Hwa et al (2017)                USA                       1995--2010   1,971         64                   HB cohort          Myeloma                                         I/II 75%, III/IV 25%                     Mixed                                                Mixed                                                                                                  549               1,733               Post-diagnostic beta-blocker use (time-fixed)           74.3                                        CT                                                                                           0.67     0.55--0.81         OS                       Yes            Demographics, disease characteristics, diagnosis year, and various chemotherapies                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        7

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       0.53     0.42--0.67         CSS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  20          Jansen et al (2014)             Germany                   2003--2007   1,975         68                   PB cohort          Colorectal cancer                               I/II 55% III/IV 45%                      Mixed 97.3%                                          Mixed: beta selective (86%); non-selective (14%)                                                       509               1,311               Pre-diagnostic beta-blocker use                         60                                          CT or RT                                                                                     0.99     0.79--1.22         OS                       Yes            Age at diagnosis, sex, Union for International Cancer Control (UICC) stage (I--IV), surgery, chemotherapy, radiotherapy, body mass index, hypertension, CVD (including heart failure, myocardial infarction, stroke, and cardiac circulatory disorder), diabetes, regular use of nonsteroidal anti-inflammatory drugs (NSAIDs) including aspirin, regular use of statins, use of hormone replacement therapy (HRT), lifetime pack-years of active smoking, physical activity (quartiles of lifetime metabolic equivalents \[METs\] in hours per week), and participation in health check-up                                              8

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       0.93     0.71--1.21         CSS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  21          Kim et al (2017)                Korea                     2001--2012   1,274         61 (20--87)          HB cohort          Head and neck squamous cell carcinoma (HNSCC)   I/II 41.4% III/IV 58.6%                  Mixed 69.2%                                          Mixed: beta 1 selective (84%); non-selective (16%)                                                     114               1,160               Post-diagnostic beta-blocker use (time-fixed)           98                                          Primary curative surgery, RT, CRT with or without IC, or a combination of these treatments   1.33     0.93--1.91         DFS                      Yes            Age, sex, BMI, CCI, smoking, alcohol, tumor site, tumor classification T3--4, nodal classification N1--3, overall TNM stage III--IV, primary treatment, second primary cancer, hypertension                                                                                                                                                                                                                                                                                                                                                                                                                                              6

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       1.49     0.99--2.22         CSS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       1.54     1.17--2.05         OS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  22          Lemeshow et al (2011)           Denmark                   Since 1943   4,179         66                   PB cohort          Melanoma                                        I/II 63.8%, III/IV 36.2%                 Mixed                                                Mixed                                                                                                  372               3,807               Pre-diagnostic beta-blocker use                         58.8                                        NR                                                                                           0.81     0.67--0.97         OS                       Yes            Age and comorbidity index score                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          7

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       0.87     0.64--1.2          CSS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  23          Melhem-Bertrandt et al (2011)   USA                       1995--2007   1,413         57 49                HB cohort          Breast cancer                                   I/II 55.6%, III/IV 44.4%                 Yes                                                  Mixed: beta selective (89%); non-selective (11%)                                                       102               1,311               Post-diagnostic beta-blocker use (time-fixed)           58.8                                        Anthracylines and taxane-based neoadjuvant CT                                                0.3      0.10--0.87         RFS                      Yes            Age, race, stage, grade, receptor status, lymphovascular invasion, body mass index, diabetes, hypertension, and angiotensin-converting enzyme inhibitor use                                                                                                                                                                                                                                                                                                                                                                                                                                                                              7

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       0.76     0.44--1.33         CSS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       0.35     0.12--1.00         OS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  24          Springate et al (2015)          NR                        1997--2006   11,302        NR                   HB cohort          Mixed cancer                                    NR                                       NR                                                   Mixed                                                                                                  4,030             7,272               Pre-diagnostic beta-blocker use                         29 30                                       NR                                                                                           1.03     0.93--1.14         OS                       No             No                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       7

  24          Springate et al (2015)          NR                        1997--2006   6,274         NR                   HB cohort          Mixed cancer                                    NR                                       NR                                                   Mixed                                                                                                  1,406             4,868               Pre-diagnostic beta-blocker use                         29 30                                       NR                                                                                           1.18     1.04--1.33         OS                       No             No                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       7

  25          Udumyan et al (2017)            Swedish                   2006--2009   2,394         70.9 67.1            PB cohort          Pancreatic adenocarcinoma                       I/II 21%, III/IV 79%                     NR                                                   Mixed: beta 1 selective (89%); non-selective (11%)                                                     522               1,872               Pre-diagnostic beta-blocker use                         5                                           NR                                                                                           0.79     0.70--0.90         OS                       Yes            Sociodemographic factors, tumor characteristics, comorbidity score, and other medications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                8

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       0.77     0.69--0.87         CSS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  26          Wang et al (2013)               USA                       1998--2010   722           65 (34--95)          HB cohort          Non-small-cell lung cancer                      I/II 6.2%, III 93.8%                     Mixed                                                Mixed: beta selective (86%); non-selective (14%)                                                       155               567                 Post-diagnostic beta-blocker use (time-fixed)           44 (1--155)                                 Definitive RT                                                                                0.91     0.64--1.31         PFS                      Yes            Age, Karnofsky performance score, clinical stage, tumor histology, use of concurrent chemotherapy, radiation dose, GTV, hypertension, chronic obstructive pulmonary disease, and aspirin consumption                                                                                                                                                                                                                                                                                                                                                                                                                                     7

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       0.67     0.50--0.91         DMFS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       0.74     0.58--0.95         DFS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       0.78     0.63--0.97         OS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  27          Watkins et al (2015)            USA                       2000--2010   1,425         61.6 68              HB cohort          Ovarian cancer                                  I/II 10%, III/IV 90%                     Yes                                                  Mixed: beta selective (72.1%); non-selective (27.9%)                                                   269               1,156               Post-diagnostic beta-blocker use (time-fixed)           NR                                          CT                                                                                           0.26     0.19--0.37         OS                       No             No                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       6

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       0.24     0.17--0.34         CSS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  28          Yusuf et al (2012)              USA                       2000--2006   456           67                   HB cohort          Mixed cancer                                    NR                                       NR                                                   NR                                                                                                     211               245                 NR                                                      1.2                                         Chest RT or CT                                                                               0.64     0.51--0.81         OS                       Yes            Age, cancer status, cancer type, previous chemotherapy, chest radiotherapy, hyperlipidemia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               6

  29          Botteri et al (2013)            Italy                     1997--2006   800           62 59                HB cohort          Breast cancer                                   I/II 86%, III/IV 14%                     Yes                                                  Mixed: beta 1 selective (84.1%); non-selective (4%); alpha and beta mixed (11.9%)                      74                726                 Pre-diagnostic beta-blocker use                         72 67.2                                     Adjuvant CT and RT                                                                           0.42     0.18--0.97         CSS                      Yes            Age, tumor stage, and treatment, peritumoral vascular invasion and use of other antihypertensive drugs, antithrombotics, and statins                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     7

  30          Spera et al (2017)              Canada                    NR           1,144         60 53                HB cohort          Breast cancer                                   NR                                       Yes                                                  Mixed                                                                                                  153               991                 Pre/post-diagnostic beta-blocker use (time-dependent)   25.1                                        CT                                                                                           0.81     0.66--0.99         PFS                      Yes            Treatment arm (RAM vs PBO), HHRR status, geographic region, THE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          7

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       1.05     0.85--1.29         OS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  31          Johannesdottir et al (2013)     Denmark                   1999--2010   6,253         65                   HB cohort          Ovarian cancer                                  NR                                       Mixed                                                NR                                                                                                     87                6,166               Pre-diagnostic beta-blocker use                         30.6                                        HRT                                                                                          1.18     0.90--1.55         OS                       Yes            Age, comorbidity level, prior use of diuretics, year of diagnosis, aspirin, and statins                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  7

  31          Johannesdottir et al (2013)     Denmark                   1999--2010   6,539         65                   HB cohort          Ovarian cancer                                  NR                                       Mixed                                                NR                                                                                                     373               6,166               Pre-diagnostic beta-blocker use                         30.6                                        HRT                                                                                          1.17     1.02--1.34         OS                       Yes            Age, comorbidity level, prior use of diuretics, year of diagnosis, aspirin, and statins                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  7

  32          Assayag et al (2014)            Canada/UK                 1998--2012   6,270         72.3                 PB cohort          Prostate cancer                                 NR                                       Yes                                                  Mixed: beta selective (59.4%); non-selective (40.6%)                                                   673               1,088               Post-diagnostic beta-blocker use (time-dependent)       45.6                                        Prostatectomy, RT, ADT, and CT                                                               0.97     0.8--1.16          OS                       No             No                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       7

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       0.97     0.72--1.31         CSS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  33          Cata et al (2014)               USA                       NR           391           NR                   HB cohort          Non-small-cell lung cancer                      I/II 75.2%, III 24.8%                    Yes                                                  Beta 1 selective                                                                                       149               242                 NR                                                      NR                                          NR                                                                                           1.304    0.973--1.747       RFS                      Yes            Age, stage of disease, BMI, ASA physical status, smoking status, CAD, postoperative radiation treatment, type of surgery, and perioperative blood transfusions                                                                                                                                                                                                                                                                                                                                                                                                                                                                           7

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       1.335    0.966--1.846       OS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  33          Cata et al (2014)               USA                       NR           286           NR                   HB cohort          Non-small-cell lung cancer                      I/II 75.2%, III 24.8%                    Yes                                                  Beta non-selective                                                                                     44                242                 NR                                                      NR                                          NR                                                                                           0.989    0.639--1.532       RFS                      Yes            Age, stage of disease, BMI, ASA physical status, smoking status, CAD, postoperative radiation treatment, type of surgery, and perioperative blood transfusions                                                                                                                                                                                                                                                                                                                                                                                                                                                                           7

  34          Heitz et al (2013)              Germany/Canada            NR           381           60                   HB cohort          Ovarian cancer                                  I/II 6.5%, III/IV 93.5%                  Yes                                                  Mixed: beta selective (84%); non-selective (16%)                                                                                                                                                                                                                                                                                              1.108    0.678--1.812       OS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

                                                                                                                                                                                                                                                                                                                                                                                                38                343                 Post-diagnostic beta-blocker use (time-fixed)           17                                          CT                                                                                           0.92     0.65--1.31         PFS                      Yes            Age, stage, grade, and cytoreduction status                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              7

  35          Heitz et al (2017)              Germany                   1999--2014   801           58 (19--90)          HB cohort          Ovarian cancer                                  I/II 43.3%, III/IV 56.7%                 Yes                                                  Beta 1 selective                                                                                                                                                                                                                                                                                                                              0.74     0.49--1.11         OS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

                                                                                                                                                                                                                                                                                                                                                                                                141               660                 NR                                                      40                                          CT                                                                                           0.94     0.69--1.29         OS                       Yes            Age, ECOG, ASA, Charlton comorbidity score (metric), tumor residuals, histology, body mass index, and FIGO stage                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         7

  36          Holmes et al (2013)             Canada                    2004--2008   2,433         68.3                 PB cohort          Breast cancer                                   NR                                       NR                                                   Mixed                                                                                                                                                                                                                                                                                                                                         0.95     0.72--1.27         PFS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  36          Holmes et al (2013)             Canada                    2004--2008   2,016         68.3                 PB cohort          Colorectal cancer                               NR                                       NR                                                   Mixed                                                                                                  123               2,310               Pre-diagnostic beta-blocker use                         NR                                          NR                                                                                           1.1      0.92--1.32         OS                       No             No                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       6

  36          Holmes et al (2013)             Canada                    2004--2008   2,125         68.3                 PB cohort          Lung cancer                                     NR                                       NR                                                   Mixed                                                                                                  152               1,864               Pre-diagnostic beta-blocker use                         NR                                          NR                                                                                           1.05     0.93--1.18         OS                       No             No                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       6

  36          Holmes et al (2013)             Canada                    2004--2008   1,868         68.3                 PB cohort          Prostate cancer                                 NR                                       NR                                                   Mixed                                                                                                  196               1,929               Pre-diagnostic beta-blocker use                         NR                                          NR                                                                                           1.01     0.93--1.11         OS                       No             No                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       6

  37          Jansen et al (2017)             The Netherlands           1998--2011   2,530         73 68                PB cohort          Colorectal cancer                               I/II 55.7%, III/IV 44.3%                 Mixed 89.8%                                          Mixed: beta selective (55%); non-selective (45%)                                                       163               1,705               Pre-diagnostic beta-blocker use                         NR                                          NR                                                                                           1.18     0.99--1.40         OS                       No             No                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       6

  37          Jansen (2017)                   The Netherlands           1998--2011   1,374         73 68                PB cohort          Colorectal cance                                I/II 55.7%, III/IV 44.3%                 Mixed 89.8%                                          Mixed: beta selective (66%); non-selective (34%)                                                       1456              1,074               Pre-diagnostic beta-blocker use                         79.2                                        NR                                                                                           1.07     0.96--1.19         OS                       Yes            Age at diagnosis, sex, year of diagnosis, socioeconomic status based on the place of residence, Union for International Cancer Control (UICC) stage (I, II, III, IV), cancer site (colon, rectum/rectosigmoid), surgery, chemotherapy, radiotherapy, cancer, cardiovascular disease, cerebrovascular disease, diabetes, hypertension, time-dependent use of NSAIDs, statins and diabetes medication after diagnosis and number of distinct ATC classes prescribed during 4 months prior to diagnosis (0, 1--3, 4--5, 6+ distinct ATC classes \[first letter of the ATC\] dispensed during 4 months prior to diagnosis)                   7

  38          Livingstone et al (2013)        Germany/The Netherlands   709          67 59         PB cohort            Melanoma           NR                                              Mixed                                    Mixed: beta 1 selective (84%); non-selective (16%)                                                                                                          919               455                 Post-diagnostic beta blocker use (time-dependent)       79.2                                        NR                                                                                           1.1      0.98--1.23         OS                       Yes            Age at diagnosis, sex, year of diagnosis, socio-economic status based on the place of residence, Union Internationale Contre le Cancer (UICC) stage (I, II, III, IV), cancer site (colon, rectum/rectosigmoid), surgery, chemotherapy, radiotherapy, previous cancer, cardiovascular disease, cerebrovascular disease, diabetes, hypertension, time- dependent use of NSAIDs, statins and diabetes medication after diagnosis and number of distinct ATC classes prescribed during four months prior to diagnosis (0, 1--3, 4--5, 6+ distinct ATC classes \[first letter of the ATC\] dispensed during four months prior to diagnosis)   7

                                                                                                                                                                                                                                                                                                                                                                                                120               589                 Post-diagnostic beta-blocker use (time-dependent)       39                                          NR                                                                                           0.82     0.55--1.24         OS                       No             No                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       6

  39          Musselman et al (2014)          Canada                    2002--2010   66,889        NR                   PB cohort          Breast cancer                                   NR                                       Yes                                                  NR                                                                                                     4,372             7,013               NR                                                      57.6 6 30.5, 43.1 6 28.7, and 53.4 6 31.0   NR                                                                                           0.99     0.87--1.13         OS                       No             No                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       6

  39          Musselman et al (2014)          Canada                    2002--2010   66,890        NR                   PB cohort          Lung cancer                                     NR                                       Yes                                                  NR                                                                                                     1,901             2,314               NR                                                      57.6 6 30.5, 43.1 6 28.7, and 53.4 6 31.0   NR                                                                                           1.06     0.91--1.24         OS                       No             No                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       6

  39          Musselman et al (2014)          Canada                    2002--2010   66,891        NR                   PB cohort          Colorectal cancer                               NR                                       Yes                                                  NR                                                                                                     22,170            30,118              NR                                                      57.6 6 30.5, 43.1 6 28.7, and 53.4 6 31.0   NR                                                                                           1.06     0.99--1.02         OS                       No             No                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       6

  40          Parker et al (2017)             USA                       2000--2010   913           65 67                HB cohort          Renal cell carcinoma                            I/II 51.6%, III/IV 48.4%                 Yes                                                  Mixed: beta 1 selective (90%); non-selective (4%); alpha and beta mixed (6%)                           104               809                 Pre-diagnostic beta-blocker use                         98.4                                        NR                                                                                           0.83     0.59--1.16         OS                       Yes            Age at surgery, sex, onstitutional symptoms, smoking history, eGFR category, ECOG performance status, Charlson score, type of surgery, tumor size, 2010 pT classification, grade, coagulative tumor necrosis                                                                                                                                                                                                                                                                                                                                                                                                                             7

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       0.78     0.43--1.41         CSS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  41          Sakellakis et al (2014)         Greece                    1983--2013   610           63 55                HB cohort          Breast cancer                                   I/II 73.6%, III/IV 26.4%                 Yes                                                  Mixed                                                                                                  47                430                 Post-diagnostic beta-blocker use (time-dependent)       24 48                                       CT                                                                                           0.849    0.537--1.343       DFS                      No             No                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       6

  42          Shah et al (2011)               UK                        1997--2009   3,462         HR                   PB cohort          Mixed cancer                                    NR                                       NR                                                   Mixed: beta selective (83%); non-selective (17%)                                                       1,406             2,056               Pre-diagnostic beta-blocker use                         NR                                          NR                                                                                           1.18     1.04--1.33         OS                       No             No                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       6

  43          Weberpals et al (2017)          Holland                   1998--2011   2,221         70.4                 PB cohort          Lung cancer                                     I/II 24.1%, III/IV 75.9%                 Mixed 17.4%                                          Mixed: beta selective (88%); non-selective (12%)                                                       1,107             1,114               Pre-diagnostic beta-blocker use                         78                                          NR                                                                                           1        0.92--1.08         OS                       Yes            Comorbidities, time-varying treatment, and distinct numbers of medications used                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          7

  43          Weberpals et al (2017)          Holland                   1998--2011   2,221         70.4                 PB cohort          Lung cancer                                     I/II 24.1%, III/IV 75.10%                Mixed 17.5%                                          Mixed: beta selective (88%); non-selective (13%)                                                       1,224             997                 Post-diagnostic beta-blocker use (time-dependent)       78                                          NR                                                                                           1.03     0.94--1.11         OS                       Yes            Comorbidities, time-varying treatment, and distinct numbers of medications used                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          7
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** NR, not reported; PB, population-based; HB, hospital-based; RT, radiation therapy; CT, chemotherapy; ADT, androgen deprivation therapy; CRT, concurrent chemoradiotherapy; IC, induction chemotherapy; GKRS, gamma knife radiosurgery; HRT, hormone replacement therapy; OS, overall survival; CSS, cancer-specific survival; DFS, disease-free survival; PFS, progression-free survival; RFS, recurrence-free survival; NOS, Newcastle--Ottawa Quality Assessment Scale; BMI, body mass index; IHD, ischemic heart disease; HT, hypertension; MBT, Metastatic brain tumors; ECOG, electrocorticogram; CVD, cardiovascular disease; GTN,GTV, gross tumor volume; RAM, Ramucirumab; PBO, Placebo; HHRR, hormonal receptor; THE, treatment emergent hypertension; ASA, American Standards Association; CAD, coronary artery disease; DM, diabetes mellitus; FIGO, International Federation of Gynecology and Obstetrics; eGFR, epidermal growth factor receptor; ATC, Anatomical Therapeutic Chemical; CCI, Charlson comorbidity index; DMFS, distant metastasis-free survivall; pT, primary tumour.

###### 

Summary of the subgroup analysis results of beta-blocker use and OS

  Variables                                            Number of studies   Number of patients   Model   Outcome (OS)        Heterogeneity           
  ---------------------------------------------------- ------------------- -------------------- ------- ------------------- --------------- ------- ---------
  Ethnicity                                                                                                                                         
   Non-Europeans                                       16                  30,607               R       0.90 (0.78--1.02)   0.106           87.2    \<0.001
   Europeans                                           8                   12,182               R       1.00 (0.89--1.12)   0.958           72.2    0.001
  Duration of drug use                                                                                                                              
   \>2 years                                           6                   8,899                F       1.03 (0.93--1.14)   0.617           0.0     0.576
   \<2 years                                           6                   10,812               R       1.01 (0.91--1.11)   0.897           54.7    0.051
  Cancer stage                                                                                                                                      
   I/II                                                11                  2,870                F       0.97 (0.89--1.06)   0.507           15.6    0.295
   III/IV                                              13                  4,835                R       1.04 (0.94--1.14)   0.468           59.1    0.003
  Sample size                                                                                                                                       
   \>1,500                                             15                  65,834               R       1.01 (0.94--1.08)   0.783           76.7    \<0.001
   \<1,500                                             18                  11,839               R       0.81 (0.66--1.00)   0.053           83.5    \<0.001
  Beta-blocker type                                                                                                                                 
   Non-selective                                       12                  17,714               R       1.04 (0.89--1.22)   0.596           75.7    \<0.001
   Selective                                           10                  17,714               R       0.93 (0.83--1.05)   0.243           83.5    \<0.001
  Chronological order of drug use                                                                                                                   
   Pre-diagnostic beta-blocker use                     13                  55,710               R       1.03 (0.95--1.11)   0.493           74.7    \<0.001
   Post-diagnostic beta-blocker use (time-fixed)       7                   6,372                R       0.65 (0.43--0.99)   0.046           91.0    \<0.001
   Post-diagnostic beta blocker use (time-dependent)   2                   2,406                R       0.87 (0.59--1.30)   0.508           76.8    0.038
  Cancer type                                                                                                                                       
   Lung cancer                                         7                   10,189               F       1.01 (0.96--1.05)   0.818           40.1    0.124
   Melanoma                                            2                   4,910                F       0.81 (0.67--0.97)   0.026           0.0     0.892
   Mixed cancer                                        4                   21,494               R       1.00 (0.83--1.21)   0.974           87.7    \<0.001
   Colorectal cancer                                   2                   4,202                R       1.16 (0.84--1.61)   0.353           51.3    0.152
   Ovarian cancer                                      5                   3,140                R       0.59 (0.36--0.96)   0.034           88.0    \<0.001
   Breast cancer                                       6                   16,637               R       0.97 (0.78--1.21)   0.783           61.20   0.024
   Pancreatic cancer                                   2                   16,096               R       0.85 (0.75--0.97)   0.014           71.10   0.063

**Abbreviations:** F, fixed-effects model; R, random-effects model; OS, overall survival.

[^1]: These authors contributed equally to this work
